Transaction in Own Shares

PureTech Health PLC

10 November 2023

 

10 November 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	9 November 2023
Number of ordinary shares purchased:	1,835
Highest price paid per share:	168.60p
Lowest price paid per share:	168.60p
Volume weighted average price paid per share:	168.60p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,196,707 ordinary shares in treasury and has 273,271,452 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,271,452 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
09/11/2023	13:08:35	634	168.6	XLON	00377768603TRLO0.1.1
09/11/2023	13:08:35	71	168.6	XLON	00377768604TRLO0.1.1
09/11/2023	13:08:35	195	168.6	XLON	00377768605TRLO0.1.1
09/11/2023	14:15:47	207	168.6	XLON	00377779945TRLO0.1.1
09/11/2023	14:21:49	243	168.6	XLON	00377781080TRLO0.1.1
09/11/2023	16:00:27	450	168.6	XLON	00377813237TRLO0.1.1
09/11/2023	16:00:27	35	168.6	XLON	00377813238TRLO0.1.1

 

END